RAS- Targeted Drug Discovery Summit Europe

Presentation time: 27 Feb 2020 at 9.30

Vaccinating Against Mutant RAS – Results from TG01 Phase I/II Trial
• Results from 32-patient TG01 trial in resected pancreatic cancer
• Robust immune responses demonstrated against KRAS
• Overview of clinical and molecular outcomes

Upcoming events

Subscribe

Share